RENX — Renalytix Balance Sheet
0.000.00%
Last trade - 00:00- £29.50m
- £32.95m
- $3.00m
Annual balance sheet for Renalytix, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 74.5 | 44.1 | 26.1 | 5.38 | 3.7 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.594 | 0.901 | 0.776 | 0.722 | 0.6 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 76 | 47.4 | 28.3 | 6.81 | 5.8 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.38 | 1.72 | 1.22 | 0.213 | 0.2 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 103 | 63.3 | 42.1 | 7.1 | 6.1 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 7.26 | 12.2 | 16.1 | 11.7 | 4.8 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 7.48 | 20.1 | 23.7 | 16.1 | 13.1 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| ESOP Debt Guarantee | |||||
| Other Equity | |||||
| Total Equity | 95.1 | 43.2 | 18.5 | -8.98 | -7 |
| Total Liabilities & Shareholders' Equity | 103 | 63.3 | 42.1 | 7.1 | 6.1 |
| Total Common Shares Outstanding |